Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 1
2022 1
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
Individualization of treatment strategies.
Fernández Ortega A, Jolis López L, Viñas Villaró G, Villanueva Vázquez R, García Arias A, González Farré X, González Jiménez S, Saura Manich C, Cortés Castán J. Fernández Ortega A, et al. Among authors: cortes castan j. Adv Ther. 2011 Sep;28 Suppl 6:19-38. doi: 10.1007/s12325-011-0033-1. Epub 2011 Sep 16. Adv Ther. 2011. PMID: 21922393 Review.
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.
Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B; TROPION-Breast01 Investigators. Bardia A, et al. J Clin Oncol. 2024 Sep 12:JCO2400920. doi: 10.1200/JCO.24.00920. Online ahead of print. J Clin Oncol. 2024. PMID: 39265124
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).
Turner N, Saura C, Aftimos P, van den Tweel E, Oesterholt M, Koper N, Colleoni M, Kaczmarek E, Punie K, Song X, Armstrong A, Bianchi G, Stradella A, Ladoire S, Lim JSJ, Quenel-Tueux N, Tan TJ, Escrivá-de-Romaní S, O'Shaughnessy J; TULIP Trial Investigators. Turner N, et al. J Clin Oncol. 2024 Oct 23:JCO2400529. doi: 10.1200/JCO.24.00529. Online ahead of print. J Clin Oncol. 2024. PMID: 39442070
SEOM clinical guidelines for the management of metastatic breast cancer 2013.
Llombart Cussac A, de la Haba Rodríguez J, Ruiz Simón A, Álvarez López I, Cortés Castán J; SEOM. Llombart Cussac A, et al. Among authors: cortes castan j. Clin Transl Oncol. 2013 Dec;15(12):1004-10. doi: 10.1007/s12094-013-1095-0. Epub 2013 Oct 23. Clin Transl Oncol. 2013. PMID: 24151043